Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?
Ilgın Koçak GöktürkIşıl Erdoğan ÖzünalAlican GöktürkAli Hakan KayaGüven YılmazOlga Meltem Akay YanarErman ÖztürkPublished in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2023)
Higher levels of IPF and TXB2 in the MPN patient group indicated platelets that could not be inhibited by aspirin. It was observed that patients under cytoreductive therapy had lower IPF values, but the expected decrease in TXB2 levels was not observed. These findings suggest that a lack of response to aspirin may be due to additional intrinsic factors rather than increased platelet turnover.
Keyphrases
- low dose
- cardiovascular events
- end stage renal disease
- idiopathic pulmonary fibrosis
- antiplatelet therapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- bone mineral density
- peritoneal dialysis
- prognostic factors
- case report
- coronary artery disease
- type diabetes
- mesenchymal stem cells
- bone marrow
- body composition